Advanced Filters
noise

pulmonary-fibrosis Clinical Trials

A listing of pulmonary-fibrosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 166 clinical trials
C Carol Bampoe, BA

Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.

18 years of age All Phase N/A
M M Overbeek

Implementation of Home Monitoring in Patients with Pulmonary Fibrosis

The objective of this study is to evaluate the impact of structurally replacing half of the outpatient clinic visits for patients with pulmonary fibrosis by home monitoring and video consultations on patient self-management and health(care) outcomes.

18 years of age All Phase N/A
E ESRA PEHLİVAN

Downhill Walking in IPF

In this study; will examine the effects of downhill walking (eccentric exercise training) on exercise capacity, quality of life, and blood lactate levels in individuals with IPF. After the initial assessment, patients will be randomized into two groups: downhill walking PR group and Standard PR Group.

18 - 75 years of age All Phase N/A
A April Riddle, BSRT

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose ([18F] FDG) and fluorine-18 Displacement Per Atom ([18F]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers …

40 - 85 years of age All Phase 1
C Crestani Bruno, MD

Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis

Currently, there is no approved treatment for COVID-19 in France, either for the acute phase, nor for the late chronic phase. the investigator suggest that nintedanib has the potential to block the development of lung fibrosis when initiated early enough to inhibit the activation of mesenchymal cells and the progression …

18 - 89 years of age All Phase 3

Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole

IPF is a progressive scarring lung condition causing coughing and breathlessness. IPF patients often have reflux disease meaning stomach acid may be breathed into the lungs, potentially damaging them. Medicines which stop stomach acid production, proton pump inhibitors (PPIs), can be used to reduce reflux symptoms including heartburn. Some researchers …

40 years of age All Phase 3

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.

40 years of age All Phase 2
T Tülay SEVİM

The Effect of Exercise Training on Quality of Life and Disease Progression in Fibrosing Interstitial Lung Patients

In this study, the progression of the disease and changes in quality of life will be examined over a 1-year follow-up period in groups of patients with Fibrosing Interstitial Lung Disease who either participated in or did not participate in a pulmonary rehabilitation program. After the initial evaluation, the patients …

18 - 75 years of age All Phase N/A

Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be confirmed. This confirmation is mandatory to validate …

18 years of age All Phase 3

SB17170 Phase 2 Trial in IPF Patients

This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or …

40 years of age All Phase 2

Simplify language using AI